期刊文献+

肺腺癌转化为小细胞肺癌一例

原文传递
导出
摘要 患者男,46岁,既往吸烟史10余年,20支/d,已戒烟1年余。2015年1月20日因“胸闷、憋气、咳嗽、咳痰2月余”就诊,行胸部增强CT示左肺癌并肺内多发转移、纵隔淋巴结转移、左侧胸膜转移、胸腔积液。行腹部增强CT未见明显异常。后行胸腔积液穿刺引流术,送检胸腔积液查见癌细胞,考虑腺癌;CT引导下行肺组织穿刺活检术,病理诊断为肺腺癌(图1),临床诊断为左肺腺癌Ⅳ期。
作者 王璇
出处 《国际肿瘤学杂志》 CAS 2018年第11期703-704,共2页 Journal of International Oncology
  • 相关文献

参考文献2

二级参考文献42

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of wordwide burden of cancerin 2008: GLOBOCAN 2008. IntJ Cancer, 2010, 127(12): 2893-2917.
  • 2Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000, 19(13): 3159-3167.
  • 3Engelman JA, Jiinne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med, 2005, 26(3 ): 314-322.
  • 4Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Y EnglJ Med, 2009, 361(10): 947-957.
  • 5Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
  • 6Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-ceU lung cancer (NSCLC). Ann Oncol, 2013, 24(6): 1615-1622.
  • 7Wood DE. National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Tnorac Surg Clin, 2015, 25(2): 185-197.
  • 8Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Meal, 2011, 3(75): 75ra26.
  • 9Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet, 2012, 44(10): 1111-1116.
  • 10Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR- mutant lung cancers. Clin Cancer Res, 2013, 19(8): 2240-2247.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部